Anti-candidal activity of essential oils alone and in combination with amphotericin B or fluconazole against multi-drug resistant isolates of Candida albicans

References

• Aperis G, Myriounis N, Spanakis EK, Mylonakis E. Developments in the treatment of candidiasis: more choices and new challenges. Expert Opin Investig Drugs 2006; 15: 1319–1336.
   PubMed Web of Science ®Google Scholar
• De Repentigny L, Lewandowski D, Jolicoeur P. Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin Microbiol Rev 2004; 17: 729–759.
   PubMed Web of Science ®Google Scholar
• Davies AN, Brailsford SR, Beighton D. Oral candidosis in patients with advanced cancer. Oral Oncol 2006; 42: 698–702.
   PubMed Web of Science ®Google Scholar
• Groll AH, Kolve H. Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Clin Microbiol Infect Dis 2004; 23: 256–270.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Natarajan-Ame S, Nivoix Y, Letscher-Bru V. The lipid formulations of amphotericin B. Expert Opin Pharmacother 2003; 4: 1277–1287.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006; 43: S3–S14.
   Web of Science ®Google Scholar
• Sobel JD, Zervos M, Reed BD, . Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob Agents Chemother 2003; 47: 34–38.
   PubMed Web of Science ®Google Scholar
• Revankar SG, Kirkpatrick WR, McAtee RK. et al. Detection and significance of fluconazole resistance in oropharangeal candidiasis in human immunodeficiency virus infected patients. J Infect Dis 1996; 174: 821–827.
   PubMed Web of Science ®Google Scholar
• Perea S, Lopez-Ribot JL, Wickes BL, . Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2002; 46: 1695–1703.
   Google Scholar
• De Logu A, Saddi M, Cardia MC, . In vitro activity of 2-cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans. J Antimicrob Chemother 2005; 55: 692–698.
   PubMed Web of Science ®Google Scholar
• Messer SA, Diekema DJ, Boyken L, . Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol 2006; 44: 324–326.
   PubMed Web of Science ®Google Scholar
• Onyewu C, Heitman J. Unique applications of novel antifungal drug combinations. Anti-infect Agents Med Chem 2007; 6: 3–15.
   Google Scholar
• Ahmad I, Khan MSA, Zahin M, . Combinational antifungal therapy and recent trends in drug discovery. Ahmad I, Owais M, Shahid M, Aqil F. Combating Fungal Infections: Problems and Remedy, 1st. Berlin Heidelberg: Springer-Verlag, 2010: 213–240.
   Google Scholar
• Mondello F, De Bernardis F, Girolamo A, Cassone A, Salvatore G. In vivo activity of terpinen-4-ol, the main bioactive component of Melaleuca alternifolia cheel (tea tree) oil against azole-susceptible and -resistant human pathogenic Candida species. BMC Infect Dis 2006; 6: 158–165.
   PubMed Web of Science ®Google Scholar
• Noumi E, Snoussi M, Hajlaoui H, Valentin E, Bakhrouf A. Antifungal properties of Salvadora persica and Juglans regia L. extracts against oral Candida strains. Eur J Clin Microbiol Infect Dis 2010; 29: 81–88.
   PubMed Web of Science ®Google Scholar
• Zhang JD, Xu Z, Cao YB, . Antifungal activities and action mechanisms of compounds from Tribulus terrestris L. J Ethnopharmacol 2006; 103: 76–84.
   PubMed Web of Science ®Google Scholar
• Khodavandi A, Alizadeh F, Aala F, Sekawi Z, Chong PP. In vitro investigation of antifungal activity of allicin alone and in combination with azoles against Candida species. Mycopathologia 2010; 169: 287–295.
   PubMed Web of Science ®Google Scholar
• Mahboubi M, Bidgoli FG. In vitro synergistic efficacy of combination of amphotericin B with Myrtus communis essential oil against clinical isolates of Candida albicans. Phytomedicine 2010; 17: 771–774.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Reference Method for Antifungal Disc Diffusion Susceptibility Testing of Yeasts. Proposed guideline M44-A2, Wayne, PA: Clinical and Laboratory Standards Institute USA, 2009.
   Google Scholar
• Sokovic M, Van Griensven LJLD. Antimicrobial activity of essential oils and their components against the three major pathogens of the cultivated button mushroom, Agaricus bisporus. Eur J Plant Pathol 2006; 116: 211–224.
   Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Proposed guideline M27-A3, Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
   Google Scholar
• Colombo AL, Barchiesel F, McGough DA, Rinaldi MG. Comparison of Etest and national committee for clinical laboratory standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol 1995; 33: 535–540.
   PubMed Web of Science ®Google Scholar
• Vitale RG, Afeltra J, Dannoui E. Antifungal combinations. Ernst EJ, Rogers PD. Antifungal Agents: Methods and Protocols, Totowa, NJ: Humana Press Inc, 2005: 143–152.
   Google Scholar
• Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
   PubMed Web of Science ®Google Scholar
• Yang YL, Li SY, Cheng HH, Lo HJ, TSARY Hospitals. The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan. BMC Infect Dis 2005; 5: 99–103.
   PubMedGoogle Scholar
• Milan EP, Burattini MN, Kallas EG, . Azole resistance among oral Candida species isolates from AIDS patients under ketoconazole exposure. Diagn Microbiol Infect Dis 1998; 32: 211–216.
   PubMedGoogle Scholar
• Swinne D, Watelle M, Nolard N. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates. Rev Iberoam Micol 2005; 22: 24–28.
   PubMedGoogle Scholar
• Hamza OJM, Matee MIN, Moshi MJ, . Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. BMC Microbiol 2008; 8: 135–143.
   PubMed Web of Science ®Google Scholar
• Tseng YH, Lee WT, Kuo TC. In-vitro susceptibility of fluconazole and amphotericin B against Candida isolates from women with vaginal candidiasis in Taiwan. J Food Drug Anal 2005; 13: 12–16.
   Web of Science ®Google Scholar
• Thakur JK, Arthanari H, Yang F, . A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature 2008; 452: 604–609.
   PubMed Web of Science ®Google Scholar
• Khan MSA, Ahmad I. Antifungal activity of essential oils and their synergy with fluconazole against drug-resistant strains of Aspergillus fumigatus and Trichophyton rubrum. Appl Microbiol Biotechnol 2011; 90: 1083–1094.
   PubMed Web of Science ®Google Scholar
• Vazquez JA. Combination antifungal therapy against Candida species: the new frontier–are we there yet? Med Mycol 2003; 41: 355–368.
   PubMed Web of Science ®Google Scholar
• Ishida K, De Mello JCP, Cortez DAG, . Influence of tannins from Stryphnodendron adstringens on growth and virulence factors of Candida albicans. J Antimicrob Chemother 2006; 58: 942–949.
   PubMed Web of Science ®Google Scholar
• Pinto E, Pina-Vaz C, Salgueiro L, . Antifungal activity of the essential oil of Thymus pulegioides on Candida, Aspergillus and dermatophyte species. J Med Microbiol 2006; 55: 1367–1373.
   PubMed Web of Science ®Google Scholar
• Rautemaa R, Richardson M, Pfaller M, Perheentupa J, Saxen H. Reduction of fluconazole susceptibility of Candida albicans in APECED patients due to long-term use of ketoconazole and miconazole. Scand J Infect Dis 2008; 40: 904–907.
   PubMed Web of Science ®Google Scholar
• Pinto PM, Weikert-Oliveira RC, Lyon JP, . In vitro antifungal susceptibility of clinical isolates of Candida spp. obtained from patients with different predisposing factors to candidosis. Microbiol Res 2008; 163: 579–585.
   PubMedGoogle Scholar